IMUNON is developing new medicines that harness the building blocks of life to work in harmony with the body’s immune system

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site.  In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.

GEN-1

Learn about our GEN-1 program under evaluation for treatment of ovarian cancer

Learn More

For Patients

OVATION 2 Study

Learn More

Latest News

See the latest news updates on IMUNON

Learn More

Latest News

Imunon Presentation at World Vaccine & Immunotherapy Congress Highlights

Read More

Imunon to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference

Read More

Imunon Announces Strategic Investment in Transomic Technologies

Read More